Table 2.
Standardized uptake value ratio values in healthy controls, patients with progressive supranuclear palsy-Richardson’s syndrome, and other disease phenotypes
| PSP-RS (n = 84) |
PSP-non-RS (n = 64) |
HCs (n = 20) |
PSP-RS versus PSP-non-RS, pa | PSP-RS versus HCs, pb | PSP-non-RS versus HCs pb | |
|---|---|---|---|---|---|---|
| Frontal cortex | 0.91 ± 0.10 | 0.89 ± 0.08 | 0.89 ± 0.07 | 0.40 | 0.90 | 0.78 |
| Parietal cortex | 0.97 ± 0.10 | 0.94 ± 0.09 | 0.93 ± 0.05 | 0.16 | 0.77 | 0.67 |
| Temporal cortex | 1.03 ± 0.12 | 1.00 ± 0.09 | 1.00 ± 0.06 | 0.35 | 0.65 | 0.90 |
| Occipital cortex | 1.10 ± 0.11 | 1.08 ± 0.09 | 1.08 ± 0.06 | 0.33 | 0.90 | 0.77 |
| Putamen | 1.29 ± 0.17 | 1.25 ± 0.14 | 1.14 ± 0.12 | 0.08 | < 0.01 | < 0.01 |
| Globus pallidus | 1.62 ± 0.21 | 1.54 ± 0.22 | 1.26 ± 0.12 | 0.01 | < 0.01* | < 0.01* |
| Thalamus | 1.66 ± 0.28 | 1.53 ± 0.25 | 1.41 ± 0.16 | 0.01 | 0.03 | 0.15 |
| Subthalamic nucleus | 1.86 ± 0.29 | 1.69 ± 0.26 | 1.34 ± 0.13 | < 0.01* | < 0.01* | < 0.01* |
| Red nucleus | 1.77 ± 0.30 | 1.62 ± 0.25 | 1.34 ± 0.09 | < 0.01 | < 0.01* | < 0.01* |
| Substantia nigra | 1.54 ± 0.20 | 1.46 ± 0.21 | 1.29 ± 0.14 | < 0.01 | < 0.01* | < 0.01 |
| Raphe nuclei | 1.74 ± 0.28 | 1.57 ± 0.27 | 1.31 ± 0.11 | < 0.01* | < 0.01* | < 0.01* |
| Locus coeruleus | 1.47 ± 0.19 | 1.36 ± 0.17 | 1.26 ± 0.14 | < 0.01* | < 0.01* | < 0.01 |
| Dentate nucleus | 1.47 ± 0.20 | 1.36 ± 0.15 | 1.32 ± 0.12 | < 0.01 | 0.13 | 0.35 |
| Cerebellar white matter | 1.35 ± 0.13 | 1.28 ± 0.11 | 1.26 ± 0.09 | < 0.01 | 0.20 | 0.69 |
a A generalized linear model adjusted for age, sex, and disease duration was used to estimate intergroup differences related to semiquantitative PET parameters in different target regions; in all analyses, the Benjamini–Hochberg procedure was applied to correct for multiple comparisons
b A generalized linear model adjusted for age and sex was used to estimate intergroup differences related to semiquantitative PET parameters in different target regions; in all analyses, the Benjamini–Hochberg procedure was applied to correct for multiple comparisons
Abbreviations: PSP-RS, progressive supranuclear palsy-Richardson’s syndrome; PSP-non-RS, other PSP subtypes with the exception of progressive supranuclear palsy-Richardson’s syndrome; HCs, healthy controls. * p < 0.0001